The Clinical Impact of Cobas® Eplex Blood Culture Panels for the Diagnosis of Bacteremia and Fungemia

Launched by UNIVERSITY HOSPITAL, ANTWERP · Aug 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how a new blood testing method called the cobas® eplex blood culture panels can improve the diagnosis and treatment of bloodstream infections, which can be serious and even life-threatening. The trial includes patients of all ages and genders who have positive blood cultures collected as part of their standard medical care. Some patients will have their blood tested using the cobas® eplex method, while others will continue to receive the traditional testing methods. The main goal is to find out if the new testing method helps doctors give the right antibiotics faster, which can lead to better outcomes for patients.

To be eligible for the trial, patients must have started showing signs of a bloodstream infection while in the emergency department or hospital, and they need to be admitted for at least 24 hours after their blood was drawn. The trial excludes patients who have passed away by the time their blood cultures come back positive or those who are not expected to survive long due to their condition. Participants can expect to undergo routine tests as part of their care, and the researchers will monitor how quickly effective treatment is given, as well as other factors like hospital stay length and overall health outcomes. This study is currently recruiting participants and aims to provide important information about the effectiveness of new blood testing technology.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with onset of BSI at the emergency department or general wards
• • Patients hospitalized from blood draw (at least 24h)
• • For pediatric patient only BSI episodes caused by gram-negative organisms
• Exclusion Criteria:
• • Patients deceased at the time of the positive blood culture
• • Patients in comfort care or with an estimated survival before sepsis of less than one month
• • Patients with positive blood culture bottles within the past 14 days
• • Patients for which the blood bottles are highly suspected of contaminants (bacterial species belonging to potential skin commensals or known environmental contaminants) and in the absence of any other site of infections.